

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

ORAL SMALL-MOLECULE 3CL_{pro} INHIBITOR SYH2055 AGAINST SAR-CoV-2 OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2055 (the “**Product**”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

SYH2055 is an oral small-molecule 3C-like protease (3CL_{pro}) inhibitor against SARS-CoV-2 developed by the Group with global independent intellectual property rights, and a global innovative drug classified as Class 1 chemical drug in China. The Product inhibits cleaving of the viral precursor proteins by acting on the SARS-CoV-2 main protease (M_{pro}/3CL_{pro}), thereby preventing viral replication and demonstrating antiviral activity against SARS-CoV-2. Preclinical studies demonstrated that the Product had potent and broad-spectrum antiviral activity against the current dominant mutant strains including Omicron BA.4 and BA.5 variants. The Product significantly decreased viral load in the lungs in animal models with SARS-CoV-2 infection and significantly improved pulmonary inflammation, which was superior to nirmatrelvir at the same dosage. The Product had significantly improved pharmacokinetic properties over nirmatrelvir in rats and cynomolgus monkeys, demonstrating the potential to overcome the shortcoming of nirmatrelvir in its requirement for co-administration with ritonavir, and thus extending the use of the drug to patients who are uncovered due to the co-administration requirement with ritonavir. Preclinical safety evaluation data also showed good safety profile of the Product.

The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible to contribute towards the efforts in the global fight against the COVID-19 pandemic.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 7 December 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.